Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 16/20 | 0.41 |
| ▸ | PGR | P06401 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25330458 | 0.82 | AR (0.41) | ARPGRTRPV4CYP11B1CYP11B2 | |
| SCHEMBL31131379 | 0.82 | AR (0.41) | ARPGRTRPV4CYP11B1CYP11B2 | |
| SCHEMBL7266136 | 0.81 | CYP2C9 (0.41) | CYP2D6CYP2C9 | |
| SCHEMBL29775990 | 0.81 | CYP2C9 (0.41) | CYP2D6CYP2C9 | |
| SCHEMBL29713463 | 0.79 | TRPV4 (0.38) | CYP2D6CYP2C9TRPV4CYP11B1CYP11B2 | |
| SCHEMBL2860228 | 0.79 | TRPV4 (0.38) | CYP2D6CYP2C9TRPV4CYP11B1CYP11B2 | |
| SCHEMBL31131413 | 0.77 | AR (0.45) | ARPGRTRPV4CYP11B1CYP11B2 | |
| SCHEMBL25330095 | 0.77 | AR (0.45) | ARPGRTRPV4CYP11B1CYP11B2 | |
| SCHEMBL23835363 | 0.76 | TRPV4 (0.36) | CYP2C9TRPV4CYP11B1CYP11B2 | |
| SCHEMBL3338605 | 0.76 | CYP11B2 (0.37) | ARTRPV4CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592452-B2 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20100152236-A1 | Cyclic amine compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-17 | — | — | US | disclosed |
| EP-1911743-A1 | CYCLIC AMINE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-04-16 | — | — | EP | disclosed |
| CN-85106878-A | The method for preparing compound | — | 1986-07-23 | — | — | CN | disclosed |
| EP-0174131-A2 | Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them | FISONS plc (GB) | 1986-03-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152236-A1 | Cyclic amine compound | AR, FSHR, NR5A1 | AR 1/4885PGR 18/4885CYP2D6 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.